Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study on the Safety of Hemlibra Subcutaneous Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors

NCT04805801 is registered in ClinicalTrials.gov with JW Pharmaceutical as lead sponsor.

NCT NCT04805801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04805801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study on the Safety of Hemlibra Subcutaneous Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors
Lead sponsor
JW Pharmaceutical
Phase
Observational
Overall status
Unknown status
Start date
August 28, 2019
Completion date
February 28, 2025
Enrollment
17 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a with inhibitor, hemophilia a without inhibitor